A groundbreaking new test is revolutionising the way brain tumours are diagnosed in the NHS, reducing what was once an eight-week waiting game down to just two hours. This revolutionary genomic approach, now being piloted across five specialist centres in England, promises to deliver life-saving results while patients are still on the operating table. For individuals like Steve Palmer, 55, from Nottingham, the difference was profound. His diagnosis of grade 4 glioblastoma was confirmed mid-surgery, sparing him weeks of excruciating uncertainty and allowing treatment to commence immediately.
A Magical Leap in Surgical Precision
The transformation is nothing short of remarkable, according to consultant neurosurgeon Stuart Smith, who led Mr Palmer’s operation at Queens Medical Centre. “The diagnosis of brain tumours relies on molecular and genetic analysis but it can take up to six to eight weeks to get the full information back,” he explained. “Here it is done while we are still operating.”
This speed fundamentally changes surgical strategy. For curable tumour types, surgeons can now pursue more aggressive removal, aiming to excise every possible trace of malignancy. Conversely, for extremely aggressive cancers, the detailed genetic profile allows for more cautious approaches, minimising the risk of damaging critical brain tissue while still providing optimal care. Dr Simon Paine, consultant neuropathologist at Nottingham University Hospitals NHS Trust, described the shift in perspective: “I’m crystal ball gazing and can do it reasonably well on a good day, but nowhere near with the clarity of the nanopore, which gives a comprehensive molecular classification.”
How the Shoebox-Sized Science Works
The process begins with small tissue samples extracted from the tumour during surgery. These specimens are transported to the pathology laboratory where they’re loaded into a compact sequencing device developed by Oxford Nanopore. The machine, roughly the size of a shoebox, uses cutting-edge technology to read the tumour’s genetic code. Special software, created through a collaboration between the University of Nottingham and hospital clinicians, guides the analysis as DNA molecules pass through microscopic pores, revealing the tumour’s unique genomic fingerprint.
In Mr Palmer’s case, after just 20 minutes of sequencing, the neuropathology team urgently contacted the operating theatre with their findings. The rapid turnaround isn’t just convenient—it’s transformative for patient care pathways. More than 12,000 people in the UK receive a primary brain tumour diagnosis each year, making this advancement critically important for a significant portion of the population.
Expanding Access Across the NHS
The pilot programme involves Nottingham University Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust, Great Ormond Street Hospital NHS Foundation Trust, King’s College Hospital, and Newcastle Hospitals NHS Foundation Trust, with plans to extend to Bristol, Oxford, Leeds and Manchester. NHS medical director Professor Frankie Swords emphasised the human impact: “For people with suspected brain tumours, getting the right diagnosis quickly can feel like a race against time, while waiting weeks for answers can be agonising for them and their families.”
This initiative represents what NHS England describes as a world-first rollout of rapid genomic testing across multiple hospitals simultaneously. Prof Dame Sue Hill, chief scientific officer for England and senior responsible officer for genomics in the NHS, noted: “This is another world-leading development for NHS genomics, taking pioneering science and testing how we can use it safely and consistently in patient care.”
Unlocking New Treatment Pathways
Beyond accelerating immediate surgical decisions, the comprehensive genetic profile enables faster access to clinical trials and personalised treatment programmes. As Dr Smith observed, “For patients it will mean not only quicker access to results and treatment, but because we have a full genetic profile of the tumour, more rapid access to clinical trials.” This genetic information helps match patients with trials specifically designed for their tumour’s molecular characteristics, potentially offering access to cutting-edge therapies that might otherwise remain unavailable.
The technology’s potential extends beyond individual patient outcomes. By establishing robust evidence for rapid genomic testing, the NHS aims to integrate this capability into routine care nationwide. This systematic approach ensures equitable access to life-saving diagnostic advances across all regions, addressing previous disparities in access to innovative treatments and research opportunities.
Why it Matters
This revolutionary diagnostic capability represents more than technological progress—it’s a fundamental shift in how we approach one of medicine’s most challenging battles. For patients facing brain tumours, particularly those under 40 who comprise the disease’s most vulnerable demographic, these hours-long diagnoses replace weeks of devastating uncertainty with actionable medical intelligence. The ability to make informed surgical decisions in real-time, coupled with expedited access to personalised treatments and clinical trials, transforms brain tumour care from reactive to proactive. Most significantly, establishing this technology as routine NHS practice ensures that every patient, regardless of their location, can benefit from this world-leading advancement—potentially saving countless lives through earlier, more precise interventions.
